[A23-107] Niraparib/abiraterone acetate (prostate cancer) – Benefit assessment according to §35a Social Code Book V
Last updated 15.02.2024
Project no.:
A23-107
Commission:
Commission awarded on 14.12.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adults with metastatic castration-resistant prostate cancer (mCRPC) and breast cancer susceptibility gene 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated
- Patients with treatment-naive mCRPC without prior taxane-containing chemotherapy: hint of considerable added benefit
- Patients with treatment-naive mCRPC with prior taxane-containing chemotherapy: added benefit not proven
- Patients with pretreated mCRPC: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://dx.doi.org/10.60584/A23-107_en
| Project no. | Title | Status |
|---|---|---|
| A24-33 | Niraparib/abiraterone acetate (prostate cancer) – Addendum to Project A23-107 | Commission completed |